Menu
ZENTAMINE (Darbepoetin Alfa) is an erythropoiesis-stimulating agent produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The final processed form is a 165-amino acid protein containing 5 N-linked oligosaccharide chains and 1 O-linked oligosaccharide chain. Darbepoetin Alfa injection causes the bone marrow to produce red blood cells in patients with severe anemia. Darbepoetin may be used for patients on kidney dialysis or for those not on dialysis.
Darbepoetin Alfa 25mcg/ 0.42ml and 40mcg/0.4ml
Darbepoetin Alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Darbepoetin Alfa binds to the erythropoietin receptor on erythroid progenitor cells, stimulating RBC production and differentiation Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
Recommended starting dose for CKD patients on dialysis: 0.45 mcg/kg intravenously or subcutaneously weekly, or 0.75 mcg/kg intravenously or subcutaneously every 2 weeks. Intravenous route is recommended for patients on hemodialysis.
Recommended starting dose for patients with CKD not on dialysis: 0.45 mcg/kg intravenously or subcutaneously at 4 week intervals.
Recommended starting dose for cancer patients on chemotherapy: 2.25 mcg/kg subcutaneously weekly, or 500 mcg subcutaneously every 3 weeks.
2ᵒC to 8ᵒC, should not be freeze
DISCLAIMER: This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.*Images/Pack are for representation purpose only.
Available in iOS & Android
